Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jeffrey Garro
STEP
Jeffrey Garro
Stephens
Wall Street Analyst
★★☆☆☆
#2002
on 13Foresight · ranked by our own returns
44%
Success Rate
-7.8%
Average Return
8 of 18 calls profitable · -17.9% vs benchmark
📈 Across the calls we could measure, roughly 44% of Jeffrey Garro's ratings turned a profit when each position was held for 1 year — averaging -7.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

6 Buy 7 Hold 0 Sell
Jeffrey's Stock Coverage 18 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
OPRX
OptimizeRx
 May 13, 2026 HOLD Strong Buy
+158.1% avg upside
9 analysts
$7.00
40.58% Upside
 +0.6%
CERT
Certara
 May 12, 2026 BUY Buy
+133.3% avg upside
21 analysts
$9.00
62.37% Upside
 +18.9%
HCAT
Health Catalyst
 May 12, 2026 HOLD Buy
+215.1% avg upside
15 analysts
$1.75
0.53% Upside
 -19.6%
TBRG
TruBridge
 Apr 13, 2026 HOLD Hold
+14.4% avg upside
9 analysts
$18.00
30.92% Downside
 +21.9%
PHR
Phreesia
 Mar 31, 2026 BUY Strong Buy
+82.2% avg upside
21 analysts
$20.00
113.30% Upside
 +4.7%
DH
Definitive Healthcare Corp
 Feb 27, 2026 HOLD Hold
+658.6% avg upside
19 analysts
$3.00
294.76% Upside
 -33.8%
EVH
Evolent Health
 Feb 25, 2026 BUY Strong Buy
+121.1% avg upside
19 analysts
$7.00
55.97% Upside
 +34.4%
SLP
Simulations Plus
 Jul 15, 2025 BUY Buy
+89.9% avg upside
11 analysts
$20.00
9.67% Upside
 +25.8%
TDOC
Teladoc
 Apr 30, 2025 HOLD Buy
+257.8% avg upside
37 analysts
$8.00
0.85% Downside
 -15.7%
PRVA
Privia Health Group
 Mar 05, 2025 BUY Strong Buy
+34.1% avg upside
26 analysts
$30.00
26.66% Upside
 -7.2%
MDRX
Veradigm
 Jan 31, 2025 HOLD Buy
+207.0% avg upside
22 analysts
$7.00
45.93% Upside
 -12.8%
DOCS
Doximity
 Dec 19, 2024 HOLD Buy
+61.4% avg upside
27 analysts
$55.00
168.72% Upside
 -20.9%
VEEV
Veeva Systems
 Dec 19, 2024 BUY Buy
+54.2% avg upside
36 analysts
$280.00
82.68% Upside
 +1.0%
IQV
IQVIA Holdings
 Dec 19, 2024 BUY Strong Buy
+34.3% avg upside
38 analysts
$250.00
49.06% Upside
 +15.2%
ALHC
Alignment Healthcare
 Aug 05, 2022 BUY Strong Buy
+1.8% avg upside
19 analysts
$20.00
8.60% Downside
 -64.0%
INNV
InnovAge Holding
 May 11, 2022 SELL Sell
-19.2% avg upside
12 analysts
$3.90
56.43% Downside
 -30.8%
SLQT
SelectQuote
 May 05, 2022 HOLD Buy
+685.4% avg upside
16 analysts
$3.00
203.57% Upside
 -48.7%
ORCL
Oracle
 Dec 20, 2021 BUY Strong Buy
+19.0% avg upside
70 analysts
 — -10.1%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Jeffrey Garro — Frequently Asked Questions
How accurate are Jeffrey Garro's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Jeffrey's ratings were profitable over a one-year hold, with an average return of -7.8% per rating, or -17.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jeffrey ranked on 13Foresight?
Jeffrey Garro is currently ranked #2002 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jeffrey cover?
Jeffrey most recently has ratings on OPRX, CERT, HCAT, TBRG, PHR, DH, EVH, SLP, TDOC, PRVA, MDRX, DOCS and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.